Infliximab MRI relaxation time in solution

Skrócona strona pozycji
dc.contributor.authorBober, Zuzanna
dc.contributor.authorBar, Piotr
dc.contributor.authorPasternak, Grzegorz
dc.contributor.authorGaliniak, Sabina
dc.contributor.authorBartusik-Aebisher, Dorota
dc.contributor.authorFilip, Rafał
dc.contributor.authorAebisher, David
dc.date.accessioned2019-04-08T12:41:45Z
dc.date.available2019-04-08T12:41:45Z
dc.date.issued2019
dc.description.abstractIntroduction. The use of Quantitative Magnetic Resonance Imaging to drug monitoring in vitro or in vivo can provides a powerful means to map the effects of drugs on tissue activity. Aim. The purpose of this study was to measure relaxation time of antibody phantom. For this purpose, infliximab sample was used. Material and methods. The selected methods to detect relaxation time of antibody was Magnetic Resonance Imaging technique. We detected spin-lattice (T1) relaxation time and discuss differences where compare to water. Results. The measurements of spin-lattice (T1) relaxation time showed significant differences. The results obtained in phantom indicate that we can use this result for measurements of relaxation time in vitro. Conclusion. Infliximab is approved for severe cases of rheumatoid arthritis, together with methotrexate, for pronounced psoriasis and psoriasis-arthritis, ankylosing spondylitis as well as for chronic inflammatory bowel disease. We conclude, that Quantitative Magnetic Resonance Imaging can be used to monitor drug effects.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 17, z. 1 (2019), s. 22–25pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2019.1.4
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/4516
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectinfliximabpl_PL.UTF-8
dc.subjectmagnetic resonance imagingpl_PL.UTF-8
dc.subjectrelaxation timepl_PL.UTF-8
dc.titleInfliximab MRI relaxation time in solutionpl_PL.UTF-8
dc.typearticlepl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
4 bober-infliximab mri.pdf
Rozmiar:
116.87 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.17, z. 1 (2019)